Seng-Lai Tan, PhD
LightNews LightNews
senglaitan.bsky.social
Seng-Lai Tan, PhD
@senglaitan.bsky.social
11 followers 22 following 5 posts
Drug Hunter/Developer & Biotech Executive | Chief Scientific Officer at TFC (The First Cell) Therapeutics
Posts Replies Media Videos
Reposted by Seng-Lai Tan, PhD
labwaggoner.bsky.social
Evidence for IL-17C governing IL-17A pathogenicity and promoting asthma endotype switching in bronchiectasis @natcomms.nature.com
www.nature.com/articles/s41...
December 26, 2025 at 6:10 PM
senglaitan.bsky.social
"The First Cell with Dr. Azra Raza” is a powerful and deeply moving call to rethink our entire approach to cancer therapy.

Professor Azra Raza co-founded TFC (The First Cell) Therapeutics:
www.youtube.com/watch?v=gUSu...
The First Cell with Dr. Azra Raza
YouTube video by John Hancock
www.youtube.com
November 23, 2025 at 8:46 PM
senglaitan.bsky.social
Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications: www.frontiersin.org/journals/imm...
Frontiers | Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications
Regulatory T cells (Tregs) are central to immune homeostasis and controlling inflammation through multiple mechanisms, however, recent discoveries and advanc...
www.frontiersin.org
August 31, 2025 at 7:47 PM
Reposted by Seng-Lai Tan, PhD
irismarchal.bsky.social
How can we engineer B cells to treat diseases? Read about the latest developments of this exciting field in this new Review out now in @natbiotech.nature.com www.nature.com/articles/s41...
Engineering B cells to treat and study human disease - Nature Biotechnology
Recent developments in B cell engineering expand our ability to study human disease and drive progress toward new B cell therapies, balancing challenges in clinical implementation with emerging opport...
www.nature.com
August 6, 2025 at 7:55 AM
senglaitan.bsky.social
How great leaders stand out.
July 24, 2025 at 9:11 PM
Reposted by Seng-Lai Tan, PhD
giorgioseano.bsky.social
🧠 Why does glioblastoma always outsmart treatment? In our #Neuro-Oncology paper, we identified proneural-mesenchymal hybrid glioblastoma cells that are resistant to therapy and dependent on nuclear import. doi.org/10.1093/neuo...
Short walkthrough below. Let’s dive in! 🧵 (1/9)
#GBM, #BrainTumor
Background: Despite extensive research efforts, glioblastoma (GBM) remains a deadly disease with poor prognosis. Although previous studies have identified various cell states within GBM tumors, the molecular mechanism underlying adaptive GBM cell plasticity induced by conventional therapy remains unclear. Methods: We used fluorescent reporters for proneural (PN) and mesenchymal (MES) subtypes to monitor GBM cell plasticity in real-time across multiple patient-derived cell lines. This approach revealed cells that concurrently expressed both proneural and mesenchymal markers. To investigate this unique hybrid population, we implemented a comprehensive methodological approach encompassing bulk and single-cell RNA sequencing, single-cell ChIP sequencing, nuclear proteomics, high-resolution imaging, orthotopic mouse models, clinical dataset analysis, and pharmacological and genetic techniques. This multifaceted strategy allowed us to gain functional and molecular insights into this distinct cellular population. Results: We showed that these hybrid cells are increased by conventional therapies, and are resistant to these therapies. At the molecular level, hybrid cells display significant alterations in chromatin structure and nuclear protein composition, elevated transcriptional activity, Myc activation, and improved transport between the nucleus and cytoplasm. Genetic and pharmaceutical inhibition of the nuclear import/export shuttling machinery, increased in hybrid cells, effectively suppressed adaptive GBM cell plasticity and hybrid identity, thereby enhancing the sensitivity of GBM cells to therapies. Conclusion: Our results indicate that GBM hybrid cells play a crucial role in chemoradiation resistance. The nuclear transport machinery presents a potential therapeutic target for hybrid cells, offering a way to counteract the typical resistance to treatment observed in GBM.
July 17, 2025 at 9:08 AM
Reposted by Seng-Lai Tan, PhD
mscherlinger.bsky.social
Thrilled to share our latest review on the treatment of systemic lupus.
Here is the open-access read : rdcu.be/ewD2J
Advances in the treatment of systemic lupus erythematosus
Nature Reviews Drug Discovery - Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations. This Review discusses advances in understanding its...
rdcu.be
July 20, 2025 at 6:29 AM
senglaitan.bsky.social
A cheatsheet for spotting a toxic leader, by George Stern.
July 13, 2025 at 10:51 PM
senglaitan.bsky.social
Great to see this paper, a long-time collaboration with Betsy Barnes' lab, is finally published, "TLR-induced STK25 activation promotes IRF5-mediated inflammation" doi.org/10.26508/lsa...
#OpenAccess #lupus #SLE @lsajournal.org
TLR-induced STK25 activation promotes IRF5-mediated inflammation
The transcription factor interferon regulatory factor 5 (IRF5) functions as an important mediator of the inflammatory response downstream of MyD88-dependent TLRs. Whereas dysregulation of IRF5 activit...
doi.org
July 11, 2025 at 12:41 PM